Soligenix

Soligenix Capital Expenditures

The Capital Expenditures (CapEx) of Soligenix (SNGX) as of Oct 17, 2026 is -5,883.00 USD.

Capital Expenditures

-5,883.00USD

Last updated:

Capital Expenditures (CapEx) of Soligenix is 2025 -5,883.00 USD. Capital Expenditures (CapEx) of Soligenix was 2024 0.00 USD. It decreases by % lower compared to the previous year.

The Soligenix Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-1,925.00 USD
Jan 1, 2019
-30,209.00 USD
Jan 1, 2020
-7,147.00 USD
Jan 1, 2021
-11,789.00 USD
Jan 1, 2022
-13,073.00 USD
Jan 1, 2023
-1.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
-5,883.00 USD
The Soligenix Capital Expenditures history
YEARCapital ExpendituresYoY
-5,883.00USD—
0.00USD-100.00%
-1.00USD-99.99%
-13,073.00USD+10.89%
-11,789.00USD+64.95%
-7,147.00USD-76.34%
-30,209.00USD+1,469.30%
-1,925.00USD-92.69%
-26,348.00USD+268.04%
-7,159.00USD-67.60%
-22,098.00USD-56.56%
-50,866.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Capital Expenditures (CapEx) of Soligenix is -5,883.00 USD in 2025.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Soligenix since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Soligenix

All Key Metrics — Soligenix